Press Releases
Company News
View Summary Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
Jan 28, 2008
PDF 10.8 KB Add to Briefcase
View Summary Medivation Names Rohan Palekar Chief Commercial Officer
Jan 15, 2008
PDF 9.0 KB Add to Briefcase
View Summary Medivation Announces Participation in Two Panel Discussions at the RBC Capital Markets 2007 Healthcare Conference
Dec 6, 2007
PDF 8.9 KB Add to Briefcase
View Summary Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Nov 5, 2007
PDF 11.8 KB Add to Briefcase
View Summary Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
Nov 3, 2007
PDF 8.7 KB Add to Briefcase
View Summary Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Oct 31, 2007
PDF 8.2 KB Add to Briefcase
View Summary Medivation Announces Participation in Upcoming Conferences
Sep 27, 2007
PDF 8.1 KB Add to Briefcase
View Summary Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
Sep 25, 2007
PDF 10.8 KB Add to Briefcase
View Summary Medivation Announces Participation in Upcoming Conferences
Sep 13, 2007
PDF 8.2 KB Add to Briefcase
View Summary Medivation Secures $100 Million Committed Equity Financing Facility
Sep 10, 2007
PDF 8.8 KB Add to Briefcase
View Summary Medivation Announces Treatment of First Patient in Phase 2 Trial of Dimebon(TM) in Huntington's Disease
Jul 30, 2007
PDF 10.9 KB Add to Briefcase
View Summary Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
Jul 25, 2007
PDF 11.4 KB Add to Briefcase
View Summary Medivation Added to Russell 2000 Index
Jul 11, 2007
PDF 8.4 KB Add to Briefcase
View Summary Medivation Names Sarvajit Chakravarty, Ph.D. Vice President of Medicinal Chemistry
Jul 9, 2007
PDF 8.7 KB Add to Briefcase
View Summary Medivation's Dimebon(TM) Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy
Jun 11, 2007
PDF 15.4 KB Add to Briefcase
View Summary Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon(TM) Alzheimer's Disease Study
Jun 5, 2007
PDF 10.3 KB Add to Briefcase
View Summary Medivation Announces Presentation of New Subset Analyses From Dimebon(TM) Phase 2 Alzheimer's Disease Trial at American Academy of Neurology Annual Meeting
May 3, 2007
PDF 14.3 KB Add to Briefcase
View Summary Medivation Announces Upcoming Conference Participation
May 3, 2007
PDF 8.0 KB Add to Briefcase
View Summary Medivation Announces First U.S. Presentation of Data From Dimebon(TM) Phase 2 Alzheimer's Disease Trial at American Academy of Neurology Annual Meeting
Apr 24, 2007
PDF 10.9 KB Add to Briefcase
View Summary Medivation CEO to Present at Leerink Swann & Company's Roundtable Conference on Alzheimer's Disease
Mar 27, 2007
PDF 10.6 KB Add to Briefcase
Showing 241-260 of 300 Page: 1 ... 9 10 11 12 13 14 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top